🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Gastric cancer: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited
2026-10-26

Phase 3 trial NCT04879368 evaluating regorafenib + nivolumab ± docetaxel/paclitaxel versus standard chemotherapy in advanced gastric cancer posted results in June 2026.

  1. Results of the phase 3 NCT04879368 trial comparing a regorafenib‑nivolumab‑docetaxel/paclitaxel regimen to standard of care chemotherapy in advanced gastric cancer were posted on 2026‑06‑10.
    If the combination shows improved efficacy or safety, it could become a new therapeutic option for patients with advanced disease. NCT04879368
  2. The trial investigated a multi‑agent strategy that adds targeted (regorafenib) and immunotherapy (nivolumab) to conventional taxane chemotherapy.
    Combining anti‑angiogenic and immune‑checkpoint blockade may overcome resistance mechanisms seen with chemotherapy alone. NCT04879368
  3. No other phase 3 gastric‑cancer trials with results posted in the past year were identified in the provided evidence.
    This underscores the limited pipeline of late‑stage gastric‑cancer studies and highlights the importance of the NCT04879368 findings. NCT04879368
  4. US drug labels for gastric cancer have been recently updated.
    Label updates can reflect new safety information, expanded indications, or dosing changes that affect clinical practice. US drug labels
  5. Emerging radioligand therapeutic approaches are being discussed as a new pillar of oncology (PMID:42927857).
    Although not yet tested in gastric cancer, this modality may represent a future avenue for targeted treatment. PMID:42927857

What to watch next

💛 A new phase 3 trial testing a combination of regorafenib, nivolumab and taxane chemotherapy has posted its results, but the specific outcomes are not yet detailed. Recent updates to US drug labels also indicate that treatment options for gastric cancer may be evolving, so discuss any changes with your oncologist.

Written by AI from the public sources cited on this page. It may be incomplete or wrong, it is not medical advice, and it does not know you. Discuss it with your doctor before making any decision. Terms of use

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
RegoNivo vs Standard of Care Chemotherapy in AGOCNCT04879368 · results posted 2026-06-10 · Australasian Gastro-Intestinal Trials Group · 462 people · tests Regorafenib, Nivolumab, Docetaxel, Paclitaxel
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111 Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinas…Ann Oncol 2026 · PMID 42926110
🏛️

US drug labels updated

A label changes when a new use, dose or warning is approved · openFDA

No label updates found.

An update is not always a new approval — open the label to see what changed.

Want these every week? Follow gastric cancer and get a note on your phone with the new trials and papers.

🔔 Follow gastric cancer
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy